ALTO NEUROSCIENCE INC (ANRO) Stock Price, Forecast & Analysis
NYSE:ANRO • US02157Q1094
ANRO Key Statistics, Chart & Performance
The current stock price of ANRO is 19.57 USD. In the past month the price increased by 17.73%. In the past year, price increased by 590%.
ANRO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ANRO. When comparing the yearly performance of all stocks, ANRO is one of the better performing stocks in the market, outperforming 99.42% of all stocks.
ANRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANRO. ANRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ANRO Financial Highlights
Over the last trailing twelve months ANRO reported a non-GAAP Earnings per Share(EPS) of -2.29. The EPS increased by 76.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.35% | ||
| ROE | -55.81% | ||
| Debt/Equity | 0.2 |
ANRO Forecast & Estimates
16 analysts have analysed ANRO and the average price target is 31.75 USD. This implies a price increase of 62.23% is expected in the next year compared to the current price of 19.57.
ANRO Ownership
ANRO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.8 | 985.228B | ||
| JNJ | JOHNSON & JOHNSON | 21.04 | 593.362B | ||
| MRK | MERCK & CO. INC. | 22.61 | 307.597B | ||
| PFE | PFIZER INC | 8.98 | 154.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.05 | 125.402B | ||
| ZTS | ZOETIS INC | 18.54 | 56.699B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.73 | 26.207B | ||
| VTRS | VIATRIS INC | 6.36 | 18.503B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 26.02 | 13.107B | ||
| AXSM | AXSOME THERAPEUTICS INC | 203.4 | 8.567B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANRO
Company Profile
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Company Info
ALTO NEUROSCIENCE INC
650 Castro Street, Suite 450
Mountain View CALIFORNIA US
Employees: 76
Phone: 17732555012
ALTO NEUROSCIENCE INC / ANRO FAQ
What does ALTO NEUROSCIENCE INC do?
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
What is the stock price of ALTO NEUROSCIENCE INC today?
The current stock price of ANRO is 19.57 USD. The price increased by 1.29% in the last trading session.
Does ALTO NEUROSCIENCE INC pay dividends?
ANRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANRO stock?
ANRO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for ALTO NEUROSCIENCE INC?
ALTO NEUROSCIENCE INC (ANRO) currently has 76 employees.
What is the ownership structure of ALTO NEUROSCIENCE INC (ANRO)?
You can find the ownership structure of ALTO NEUROSCIENCE INC (ANRO) on the Ownership tab.